EpCAMhigh and EpCAMlow circulating tumour cells in metastatic prostate and breast cancer patients

Sanne Mutter, Mariangela Manicone, Elisabetta Rossi, Rita Lampignano (Corresponding Author), Anne Margreet Sofie Berghuis, Kiki Carlijn Andree, Maarten Joost IJzerman, Leonardus Wendelinus Mathias Marie Terstappen (Corresponding Author)

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
10 Downloads (Pure)

Abstract

The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow CTC using CellSearch, followed by microfiltration of the EpCAMhigh CTC depleted blood. Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients were processed at six participating sites, using protocols and tools developed in the CTC-Trap program. Of the prostate cancer patients, 53% had ≥5 EpCAMhigh CTC and 28% had ≥5 EpCAMlow CTC. For breast cancer patients, 32% had ≥5 EpCAMhigh CTC and 36% had ≥5 EpCAMlow CTC. 70% of prostate cancer patients and 64% of breast cancer patients had in total ≥5 EpCAMhigh and/or EpCAMlow CTC, increasing the number of patients in whom CTC are detected. Castration-resistant prostate cancer patients with ≥5 EpCAMhigh CTC had shorter overall survival versus those with <5 EpCAMhigh CTC (p = 0.000). However, presence of EpCAMlow CTC had no relation with overall survival. This emphasizes the importance to demonstrate the relation with clinical outcome when presence of CTC identified with different technologies are reported, as different CTC subpopulations can have different relations with clinical outcome.
Original languageEnglish
Pages (from-to)35705-35716
Number of pages12
JournalOncotarget
Volume9
Issue number86
DOIs
Publication statusPublished - 2 Nov 2018

Fingerprint

Circulating Neoplastic Cells
Prostatic Neoplasms
Breast Neoplasms
Castration

Keywords

  • Circulating tumor cells (CTC)
  • EpCAM
  • castrate-resistant prostate cancer (CRPC)
  • metastatic breast cancer (mBC)
  • Epithelial-to-mesenchymal transition (EMT)

Cite this

Mutter, Sanne ; Manicone, Mariangela ; Rossi, Elisabetta ; Lampignano, Rita ; Berghuis, Anne Margreet Sofie ; Andree, Kiki Carlijn ; IJzerman, Maarten Joost ; Terstappen, Leonardus Wendelinus Mathias Marie. / EpCAMhigh and EpCAMlow circulating tumour cells in metastatic prostate and breast cancer patients. In: Oncotarget. 2018 ; Vol. 9, No. 86. pp. 35705-35716.
@article{a8a041a963c14e0f9c6a7b3ebe624dc7,
title = "EpCAMhigh and EpCAMlow circulating tumour cells in metastatic prostate and breast cancer patients",
abstract = "The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch{\circledR} in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow CTC using CellSearch, followed by microfiltration of the EpCAMhigh CTC depleted blood. Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients were processed at six participating sites, using protocols and tools developed in the CTC-Trap program. Of the prostate cancer patients, 53{\%} had ≥5 EpCAMhigh CTC and 28{\%} had ≥5 EpCAMlow CTC. For breast cancer patients, 32{\%} had ≥5 EpCAMhigh CTC and 36{\%} had ≥5 EpCAMlow CTC. 70{\%} of prostate cancer patients and 64{\%} of breast cancer patients had in total ≥5 EpCAMhigh and/or EpCAMlow CTC, increasing the number of patients in whom CTC are detected. Castration-resistant prostate cancer patients with ≥5 EpCAMhigh CTC had shorter overall survival versus those with <5 EpCAMhigh CTC (p = 0.000). However, presence of EpCAMlow CTC had no relation with overall survival. This emphasizes the importance to demonstrate the relation with clinical outcome when presence of CTC identified with different technologies are reported, as different CTC subpopulations can have different relations with clinical outcome.",
keywords = "Circulating tumor cells (CTC), EpCAM, castrate-resistant prostate cancer (CRPC), metastatic breast cancer (mBC), Epithelial-to-mesenchymal transition (EMT)",
author = "Sanne Mutter and Mariangela Manicone and Elisabetta Rossi and Rita Lampignano and Berghuis, {Anne Margreet Sofie} and Andree, {Kiki Carlijn} and IJzerman, {Maarten Joost} and Terstappen, {Leonardus Wendelinus Mathias Marie}",
year = "2018",
month = "11",
day = "2",
doi = "10.18632/oncotarget.26298",
language = "English",
volume = "9",
pages = "35705--35716",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "86",

}

EpCAMhigh and EpCAMlow circulating tumour cells in metastatic prostate and breast cancer patients. / Mutter, Sanne ; Manicone, Mariangela; Rossi, Elisabetta; Lampignano, Rita (Corresponding Author); Berghuis, Anne Margreet Sofie; Andree, Kiki Carlijn; IJzerman, Maarten Joost; Terstappen, Leonardus Wendelinus Mathias Marie (Corresponding Author).

In: Oncotarget, Vol. 9, No. 86, 02.11.2018, p. 35705-35716.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - EpCAMhigh and EpCAMlow circulating tumour cells in metastatic prostate and breast cancer patients

AU - Mutter, Sanne

AU - Manicone, Mariangela

AU - Rossi, Elisabetta

AU - Lampignano, Rita

AU - Berghuis, Anne Margreet Sofie

AU - Andree, Kiki Carlijn

AU - IJzerman, Maarten Joost

AU - Terstappen, Leonardus Wendelinus Mathias Marie

PY - 2018/11/2

Y1 - 2018/11/2

N2 - The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow CTC using CellSearch, followed by microfiltration of the EpCAMhigh CTC depleted blood. Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients were processed at six participating sites, using protocols and tools developed in the CTC-Trap program. Of the prostate cancer patients, 53% had ≥5 EpCAMhigh CTC and 28% had ≥5 EpCAMlow CTC. For breast cancer patients, 32% had ≥5 EpCAMhigh CTC and 36% had ≥5 EpCAMlow CTC. 70% of prostate cancer patients and 64% of breast cancer patients had in total ≥5 EpCAMhigh and/or EpCAMlow CTC, increasing the number of patients in whom CTC are detected. Castration-resistant prostate cancer patients with ≥5 EpCAMhigh CTC had shorter overall survival versus those with <5 EpCAMhigh CTC (p = 0.000). However, presence of EpCAMlow CTC had no relation with overall survival. This emphasizes the importance to demonstrate the relation with clinical outcome when presence of CTC identified with different technologies are reported, as different CTC subpopulations can have different relations with clinical outcome.

AB - The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow CTC using CellSearch, followed by microfiltration of the EpCAMhigh CTC depleted blood. Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients were processed at six participating sites, using protocols and tools developed in the CTC-Trap program. Of the prostate cancer patients, 53% had ≥5 EpCAMhigh CTC and 28% had ≥5 EpCAMlow CTC. For breast cancer patients, 32% had ≥5 EpCAMhigh CTC and 36% had ≥5 EpCAMlow CTC. 70% of prostate cancer patients and 64% of breast cancer patients had in total ≥5 EpCAMhigh and/or EpCAMlow CTC, increasing the number of patients in whom CTC are detected. Castration-resistant prostate cancer patients with ≥5 EpCAMhigh CTC had shorter overall survival versus those with <5 EpCAMhigh CTC (p = 0.000). However, presence of EpCAMlow CTC had no relation with overall survival. This emphasizes the importance to demonstrate the relation with clinical outcome when presence of CTC identified with different technologies are reported, as different CTC subpopulations can have different relations with clinical outcome.

KW - Circulating tumor cells (CTC)

KW - EpCAM

KW - castrate-resistant prostate cancer (CRPC)

KW - metastatic breast cancer (mBC)

KW - Epithelial-to-mesenchymal transition (EMT)

U2 - 10.18632/oncotarget.26298

DO - 10.18632/oncotarget.26298

M3 - Article

VL - 9

SP - 35705

EP - 35716

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 86

ER -